Clinical Trials Logo
  1. Home
  2. Advanced Cancer
  3. NCT03503149
  4. Details
NCT03503149 Clinical Trial

Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Advanced Cancer Clinical Trial

— MTB@ZPM  

Official title:
Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03503149
Other study ID # ZPM-001
Secondary ID
Status Recruiting
Phase
First received March 23, 2018
Last updated April 18, 2018
Start date March 1, 2018
Est. completion date March 1, 2028

Study information
Verified date March 2018
Source University Hospital Tuebingen
Contact Ghazaleh Tabatabai, Prof
Phone 0049707129
Email ghazaleh.tabatabai@med.uni-tuebingen.de
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Molecular Tumor Board at the Center for Personalized Medicine

Description:

Molecular Tumor Board at the Center for Personalized Medicine The study objectives are

- To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care

- To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)

- To prospectively assess patient-reported outcome of MTB patients

- To evaluate compliance to MTB suggestions in routine clinical care

Recruitment information / eligibility
Status Recruiting
Enrollment 1000
Est. completion date March 1, 2028
Est. primary completion date March 1, 2028
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Given informed consent ("broad consent" of the University Hospital Tübingen)

- = 18 years of age

- Clinical indication for a referral to Molecular Tumor Board by the treating physician

Exclusion Criteria:

- The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• no intervention
observational study

Locations
Country Name City State
Germany University Hospital Tübingen Tübingen BW

Sponsors (1)
Lead Sponsor Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Progression-free survival Progression-free survival 6 months
Secondary Overall survival Progression-free survival an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Completed NCT01901237 - Yoga for Adolescent and Young Adult Non-Curative Cancer Patients N/A
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1